PL3233852T3 - Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania - Google Patents

Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania

Info

Publication number
PL3233852T3
PL3233852T3 PL15810660T PL15810660T PL3233852T3 PL 3233852 T3 PL3233852 T3 PL 3233852T3 PL 15810660 T PL15810660 T PL 15810660T PL 15810660 T PL15810660 T PL 15810660T PL 3233852 T3 PL3233852 T3 PL 3233852T3
Authority
PL
Poland
Prior art keywords
indoles
pyrido
tetrahydro
estrogen receptor
receptor modulators
Prior art date
Application number
PL15810660T
Other languages
English (en)
Inventor
Simon Charles Goodacre
Sharada Labadie
Jun Liang
Daniel Fred Ortwine
Nicholas Charles Ray
Xiaojing Wang
Jason ZBIEG
Birong Zhang
Kwong Wah LAI
Jiangpeng LIAO
Zhiguo Liu
John Sui-Man WAI
Tao Wang
Jun Li
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of PL3233852T3 publication Critical patent/PL3233852T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL15810660T 2014-12-18 2015-12-17 Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania PL3233852T3 (pl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462093929P 2014-12-18 2014-12-18
US201562110998P 2015-02-02 2015-02-02
US201562142077P 2015-04-02 2015-04-02
EP15810660.9A EP3233852B1 (en) 2014-12-18 2015-12-17 Tetrahydro-pyrido[3,4-b]indoles as estrogen receptor modulators and uses thereof
PCT/EP2015/080119 WO2016097072A1 (en) 2014-12-18 2015-12-17 TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF

Publications (1)

Publication Number Publication Date
PL3233852T3 true PL3233852T3 (pl) 2020-12-14

Family

ID=54850193

Family Applications (1)

Application Number Title Priority Date Filing Date
PL15810660T PL3233852T3 (pl) 2014-12-18 2015-12-17 Tetrahydropirydo[3,4-b]indole jako modulatory receptora estrogenowego i ich zastosowania

Country Status (33)

Country Link
US (4) US9980947B2 (pl)
EP (2) EP3233852B1 (pl)
JP (4) JP6679147B2 (pl)
KR (4) KR102559719B1 (pl)
CN (6) CN112375078B (pl)
AU (3) AU2015367509B2 (pl)
BR (1) BR112017007662B1 (pl)
CA (1) CA2963736A1 (pl)
CL (2) CL2017000814A1 (pl)
CO (1) CO2017003070A2 (pl)
CR (1) CR20170250A (pl)
DK (1) DK3233852T3 (pl)
EA (1) EA032311B1 (pl)
ES (1) ES2819448T3 (pl)
HR (1) HRP20201396T1 (pl)
HU (1) HUE050466T2 (pl)
IL (5) IL287326B2 (pl)
LT (1) LT3233852T (pl)
MA (1) MA53837A (pl)
MX (3) MX376763B (pl)
MY (1) MY198354A (pl)
NZ (1) NZ769496A (pl)
PE (1) PE20171330A1 (pl)
PH (1) PH12017501140A1 (pl)
PL (1) PL3233852T3 (pl)
PT (1) PT3233852T (pl)
RS (1) RS60824B1 (pl)
SG (3) SG10201913913VA (pl)
SI (1) SI3233852T1 (pl)
TW (5) TWI875674B (pl)
UA (1) UA122868C2 (pl)
WO (1) WO2016097072A1 (pl)
ZA (1) ZA202108745B (pl)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN112375078B (zh) 2014-12-18 2023-12-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
KR102710603B1 (ko) * 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
JP2019001715A (ja) * 2015-10-30 2019-01-10 協和発酵キリン株式会社 三環性化合物
NZ743651A (en) 2015-12-09 2023-07-28 Univ Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017136688A1 (en) 2016-02-05 2017-08-10 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof
MA46479A (fr) 2016-02-15 2019-08-14 Sanofi Sa Procédés et intermédiaires pour la préparation de nouveaux composés substitués de 6,7-dihydro-5h-benzo[7]annulène
US10125135B2 (en) 2016-04-20 2018-11-13 Astrazeneca Ab Chemical compounds
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
ES2989988T3 (es) 2016-05-10 2024-11-28 C4 Therapeutics Inc Degronímeros heterorocíclicos para la degradación de proteínas diana
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017197051A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
WO2017216280A1 (en) * 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN107543871A (zh) * 2016-06-29 2018-01-05 重庆华邦胜凯制药有限公司 分离测定帕布昔利布中间体z1及其有关物质的方法
EA201990187A1 (ru) 2016-07-01 2019-07-31 Г1 Терапьютикс, Инк. Антипролиферационные средства на основе пиримидина
US10149839B2 (en) 2016-07-25 2018-12-11 Astrazeneca Ab Chemical compounds
JP2019532934A (ja) * 2016-09-27 2019-11-14 ラジウス ヘルス，インコーポレイテッド 卵巣癌を治療するための方法
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
LT3640251T (lt) * 2016-10-24 2022-03-10 Astrazeneca Ab 6,7,8,9-tetrahidro-3h-pirazolo[4,3-f]izochinolino dariniai, tinkami vėžio gydymui
CN110139863B (zh) * 2016-10-28 2022-02-18 罗欣健康科技发展(北京)有限公司 作为雌激素受体降解剂的吲哚并取代哌啶类化合物
KR102477513B1 (ko) * 2016-11-17 2022-12-16 사노피 신규 치환된 n-(3-플루오로프로필)-피롤리딘 화합물, 그의 제조 방법 및 그의 치료 용도
WO2018108954A1 (en) 2016-12-12 2018-06-21 F. Hoffmann-La Roche Ag Process for the preparation of 2-(3-(fluoromethyl)azetidin-1-yl)ethan-1-ol
EA037533B9 (ru) * 2016-12-16 2021-05-27 Астразенека Аб 6,7,8,9-ТЕТРАГИДРО-3H-ПИРАЗОЛО[4,3-f]ИЗОХИНОЛИНОВЫЕ ПРОИЗВОДНЫЕ, ПРИМЕНИМЫЕ В ЛЕЧЕНИИ РАКА
TWI823845B (zh) 2017-01-06 2023-12-01 美商G1治療公司 用於治療癌症的組合療法
WO2018130123A1 (zh) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的五环类化合物及其应用
WO2018138739A1 (en) 2017-01-27 2018-08-02 Sun Pharma Advanced Research Company Limited Novel antiestrogenic heterocyclic compounds
MX2019008438A (es) * 2017-01-30 2019-10-30 Astrazeneca Ab Moduladores del receptor de estrogeno.
WO2018148576A1 (en) 2017-02-10 2018-08-16 G1 Therapeutics, Inc. Benzothiophene estrogen receptor modulators
CN110769822A (zh) 2017-06-20 2020-02-07 C4医药公司 用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP4455146A3 (en) 2017-06-29 2025-01-01 G1 Therapeutics, Inc. Morphic forms of git38 and methods of manufacture thereof
EP3434272A1 (en) 2017-07-25 2019-01-30 Sanofi Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid
NZ764463A (en) 2017-11-14 2023-07-28 Kind Pharmaceutical Heterocyclic compound and application thereof in medicine
EA038160B1 (ru) * 2017-11-30 2021-07-15 Астразенека Аб Модуляторы рецептора эстрогена
US10519152B2 (en) 2017-12-21 2019-12-31 Astrazeneca Ab Compounds and their use in treating cancer
CN112105607B (zh) 2018-01-22 2024-08-27 雷迪厄斯制药公司 雌激素受体调节化合物
WO2019192533A1 (zh) * 2018-04-04 2019-10-10 深圳福沃药业有限公司 用于治疗乳腺癌的雌激素受体降解剂
CN112566666A (zh) 2018-05-14 2021-03-26 努瓦申生物公司 靶向抗癌核激素受体的化合物
IL278063B2 (en) * 2018-06-21 2025-08-01 Hoffmann La Roche Solid forms of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol and processes for preparing fused tricyclic compounds comprising a substituted phenyl or pyridinyl moiety, including methods of their use
TWI702219B (zh) * 2018-07-12 2020-08-21 美商美國禮來大藥廠 選擇性雌激素受體降解劑
KR102754524B1 (ko) * 2018-08-17 2025-01-13 제넨테크, 인크. 유방암 치료를 위한 진단 및 치료 방법들
AR116299A1 (es) 2018-09-07 2021-04-21 Sanofi Sa Sales de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo y proceso de preparación de las mismas
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN120698983A (zh) 2018-12-20 2025-09-26 C4医药公司 靶向蛋白降解
EP3930719B1 (en) * 2019-02-27 2025-08-20 Takeda Pharmaceutical Company Limited Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
JP2022532342A (ja) 2019-05-14 2022-07-14 ニューベイション・バイオ・インコーポレイテッド 抗がん核内ホルモン受容体標的化化合物
US12358875B2 (en) * 2019-06-17 2025-07-15 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as GPR17 modulators for treating CNS disorders such as multiple sclerosis
JP7616794B2 (ja) * 2019-07-07 2025-01-17 オレマ ファーマシューティカルズ インク． エストロゲン受容体アンタゴニストのレジメン
EP4003996B1 (en) 2019-07-22 2025-05-21 Radius Pharmaceuticals, Inc. Estrogen receptor-modulating compounds
US11278532B2 (en) 2019-08-06 2022-03-22 Recurium Ip Holdings, Llc Estrogen receptor modulators for treating mutants
WO2021055749A1 (en) * 2019-09-19 2021-03-25 Totus Medicines Inc. Therapeutic conjugates
WO2021063967A1 (en) 2019-10-01 2021-04-08 Sanofi Novel substituted 6,7-dihydro-5h-benzo[7]annulene compounds, processes for their preparation and therapeutic uses thereof
TW202131930A (zh) 2019-11-13 2021-09-01 美商諾維雪碧歐公司 抗癌核荷爾蒙受體標靶化合物
CA3160897A1 (en) 2019-12-09 2021-06-17 Sanofi Crystalline form of a 7h-benzo[7]annulene-2-carboxylic acid derivative
BR112022012278A2 (pt) * 2019-12-20 2022-08-30 Recurium Ip Holdings Llc Combinações
MX2022007659A (es) 2019-12-20 2022-07-19 C4 Therapeutics Inc Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
TW202140448A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 並環醯亞胺類衍生物、其製備方法及其在醫藥上的應用
TW202140475A (zh) * 2020-01-16 2021-11-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合醯亞胺類衍生物、其製備方法及其在醫藥上的應用
TW202146007A (zh) 2020-02-27 2021-12-16 法商賽諾菲公司 包含阿培利司（ａｌｐｅｌｉｓｉｂ）與６－（２，４－二氯苯基）－５－［４－［（３ｓ）－１－（３－氟丙基）吡咯啶－３－基］氧苯基］－８，９－二氫－７ｈ－苯并［７］輪烯－２－羧酸之組合
MX2022010952A (es) 2020-03-05 2022-10-07 C4 Therapeutics Inc Compuestos para la degradacion dirigida de brd9.
EP4114391B1 (en) * 2020-03-06 2025-07-09 Olema Pharmaceuticals, Inc. Compositions for use in a method of treating an estrogen receptor associated cancer
CN115667275B (zh) * 2020-04-21 2024-02-23 南京再明医药有限公司 含硼化合物及其应用
JP7719796B2 (ja) 2020-04-24 2025-08-06 アストラゼネカ・アクチエボラーグ 医薬製剤
IL297216A (en) 2020-04-24 2022-12-01 Astrazeneca Ab Dosage regimen for the treatment of cancer
IL298071A (en) * 2020-05-12 2023-01-01 Genentech Inc Treatment of breast cancer using combination therapies comprising gdc-9545 and a cdk4/6 inhibitor
CN120665066A (zh) * 2020-05-15 2025-09-19 南京再明医药有限公司 吡咯烷类化合物及其应用
TW202214626A (zh) * 2020-06-12 2022-04-16 大陸商江蘇先聲藥業有限公司 雌激素受體調節劑化合物及其用途
EP4172144A2 (en) 2020-06-30 2023-05-03 Genentech, Inc. Processes for making serd tricyclic compounds having a substituted phenyl or pyridinyl moiety
JP2023538517A (ja) 2020-08-05 2023-09-08 シーフォー セラピューティクス， インコーポレイテッド Ｒｅｔの標的分解のための化合物
CN114105977B (zh) * 2020-08-28 2023-09-01 先声再明医药有限公司 雌激素受体调节剂化合物及其用途
JP2024502270A (ja) * 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬
WO2022166983A1 (zh) * 2021-02-08 2022-08-11 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
JP2024506385A (ja) 2021-02-16 2024-02-13 ジェネンテック， インコーポレイテッド Ｇｄｃ－９５４５及びｇｄｃ－００７７を含む併用療法を使用する乳がんの治療
US12006314B2 (en) 2021-05-03 2024-06-11 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
CN117940133A (zh) 2021-06-08 2024-04-26 C4医药公司 用于突变braf的降解的治疗剂
TW202317539A (zh) * 2021-07-15 2023-05-01 大陸商四川海思科製藥有限公司 芳氨基衍生物雌激素受體調節劑及其用途
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물
CN118317948A (zh) * 2021-10-08 2024-07-09 阿佐拉治疗股份有限公司 芳烃受体激动剂的衍生物
CN118119620A (zh) * 2021-11-12 2024-05-31 南京再明医药有限公司 用于治疗肿瘤的药物组合及其应用
WO2023091550A1 (en) * 2021-11-18 2023-05-25 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-associated diseases
JP7805677B2 (ja) * 2021-12-28 2026-01-26 浙江揚歴医薬技術有限公司 テトラヒドロシクロヘプタインダゾール化合物の結晶
CN116804008A (zh) * 2022-03-24 2023-09-26 烟台创和生物科技有限公司 雌激素受体降解剂及其制备方法和应用
EP4514792A1 (en) 2022-04-28 2025-03-05 F. Hoffmann-La Roche AG Solid form of 3-((1r,3r)-1-(2,6-difluoro-4-((1-(3- fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9- tetrahydro-2h-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol tartrate
WO2023221123A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Crystalline forms of an estrogen receptor antagonist
WO2023221122A1 (en) * 2022-05-20 2023-11-23 Olema Pharmaceuticals, Inc. Salts and solid forms of an estrogen receptor antagonist
WO2024015506A1 (en) * 2022-07-14 2024-01-18 Olema Pharmaceuticals, Inc. Methods of treating estrogen receptor-mediated disorders
WO2024017131A1 (zh) * 2022-07-21 2024-01-25 贝达药业股份有限公司 杂芳基并哌啶类衍生物及其药物组合物和应用
CN115109058B (zh) * 2022-07-27 2023-04-07 黑龙江中医药大学 一种用于治疗胃癌的药物及其制备方法
EP4565585A1 (en) 2022-08-03 2025-06-11 Bristol-Myers Squibb Company Compounds for modulating ret protein
EP4573091A1 (en) * 2022-08-19 2025-06-25 Olema Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
AU2023324856A1 (en) * 2022-08-19 2025-01-30 Olema Pharmaceuticals, Inc. 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole derivatives as estrogen receptor modulators for the treatment of cancer
EP4577542A1 (en) * 2022-08-25 2025-07-02 Sanofi Novel substituted 2,3,4,9-tetrahydro-1h-pyrido[3,4-b]indole carboxylic acid derivatives, processes for their preparation and therapeutic uses thereof
IL320302A (en) 2022-10-17 2025-06-01 Astrazeneca Ab SERD combinations for cancer treatment
WO2024088392A1 (zh) * 2022-10-28 2024-05-02 南京再明医药有限公司 用于治疗肿瘤的药物组合、药物组合物及其用途
JP2025540907A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
CN120530116A (zh) 2022-11-04 2025-08-22 百时美施贵宝公司 Ret-ldd蛋白抑制剂
CN120187416A (zh) 2022-11-11 2025-06-20 阿斯利康(瑞典)有限公司 用于治疗癌症的组合疗法
US20240180893A1 (en) 2022-11-17 2024-06-06 Astrazeneca Ab Methods of treatment of breast cancer
CN115894485B (zh) * 2023-03-03 2023-06-27 山东绿叶制药有限公司 杂芳基并哌啶类衍生物、其制备方法及其在医药上的应用
US11773092B1 (en) 2023-03-27 2023-10-03 King Faisal University Pyrido[3,4-b]indol-1-one compounds as antibacterial agents
AU2024268579A1 (en) 2023-05-11 2026-01-15 Astrazeneca Ab Combination of a parp1 inhibitor and a selective estrogen degrader for treating cancer
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025103409A1 (zh) * 2023-11-16 2025-05-22 南京同诺康医药科技有限公司 Nmt抑制剂及其制备方法和用途
WO2025189056A1 (en) 2024-03-08 2025-09-12 Halda Therapeutics Opco, Inc. Heterobifunctional compounds and their use in treating disease
CN118791392B (zh) * 2024-06-18 2026-02-17 华中科技大学 一种合成依拉司群的方法及中间体化合物
US20260008798A1 (en) 2024-07-02 2026-01-08 Hoffmann-La Roche Inc. Palladium catalyzed synthesis of aminoaldehyde intermediates

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE398789C (de) 1923-03-03 1924-07-15 L V Kramolin Verfahren und Einrichtung zur Verhinderung des Mithoerens beim Telephon- und Telegraphenverkehr mittels elektrischer Wellen und zum Vielfachverkehr mittels elektromagnetischer Wellen
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
SE455604B (sv) 1982-06-29 1988-07-25 Stiftelsen Ind Organisk Elektr Sett att framstella fenetylaminer medelst elektrokemisk reduktion
US5206377A (en) 1991-12-05 1993-04-27 Whitby Research, Inc. Compounds useful as antiproliferative agents
EP0620222A3 (en) 1993-04-14 1995-04-12 Lilly Co Eli Tetrahydro-beta-carbolines.
IL115582A0 (en) * 1994-10-14 1996-01-19 Lilly Co Eli Methods for treating resistant tumors
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
WO2002062339A1 (en) 2000-12-08 2002-08-15 Smithkline Beecham Corporation Antibacterial compounds
JP4220779B2 (ja) 2001-02-12 2009-02-04 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
US6951961B2 (en) 2002-05-17 2005-10-04 Marina Nikolaevna Protopopova Methods of use and compositions for the diagnosis and treatment of infectious disease
TWI329111B (en) 2002-05-24 2010-08-21 X Ceptor Therapeutics Inc Azepinoindole and pyridoindole derivatives as pharmaceutical agents
EP1618090A1 (en) 2003-04-11 2006-01-25 Novo Nordisk A/S 11ß-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ACTIVE COMPOUNDS
WO2005034857A2 (en) 2003-09-05 2005-04-21 Sequella, Inc. Methods and compositions comprising diamines as new anti-tubercular therapeutics
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
ZA200608176B (en) * 2004-03-15 2008-05-28 Ptc Therapeutics Inc Carboline derivatives useful in the inhibition of angiogenesis
US7767689B2 (en) * 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076352B2 (en) * 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
WO2006015035A1 (en) 2004-08-02 2006-02-09 Smithkline Beecham Corporation Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
DE602006021205D1 (de) 2005-10-07 2011-05-19 Exelixis Inc Azetidine als mek-inhibitoren bei der behandlung proliferativer erkrankungen
EA018573B1 (ru) 2006-09-22 2013-09-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
EP2139476A1 (en) 2007-04-13 2010-01-06 PTC Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
EP2722333A1 (en) 2008-04-29 2014-04-23 Novartis AG Spiro-indole derivatives for the treatment of parasitic diseases.
US9292307B2 (en) 2008-07-30 2016-03-22 Kyocera Corporation User interface generation apparatus
WO2010015815A2 (en) 2008-08-05 2010-02-11 Summit Corporation Plc Compounds for the treatment of flaviviral infections
WO2010015816A2 (en) 2008-08-06 2010-02-11 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
WO2010029313A1 (en) 2008-09-11 2010-03-18 Summit Corporation Plc. Antiinfective compounds
WO2010049678A2 (en) 2008-10-31 2010-05-06 Summit Corporation Plc Treatment of energy utilization diseases
US20120040916A1 (en) 2008-12-22 2012-02-16 Massachusetts Institute Of Technology Molecular inhibitors of the wnt/beta-catenin pathway
WO2010075286A1 (en) 2008-12-24 2010-07-01 University Of Washington MOLECULAR ACTIVATORS OF THE Wnt/β-CATENIN PATHWAY
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
EP2414044A1 (en) 2009-03-31 2012-02-08 ArQule, Inc. Substituted indolo-piperidine compounds
WO2010138659A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating brain tumors
WO2010138652A1 (en) 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating kaposi sarcoma
MX373926B (es) * 2009-05-27 2020-07-10 Ptc Therapeutics Inc Metodos para tratar cancer y estados no neoplasicos.
US20120202801A1 (en) * 2009-05-27 2012-08-09 Liangxian Cao Methods for treating breast cancer
US8703726B2 (en) 2009-05-27 2014-04-22 Ptc Therapeutics, Inc. Methods for treating prostate conditions
WO2010138695A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating neurofibromatosis
US20130171103A1 (en) 2010-05-27 2013-07-04 Ptc Therapeutics, Inc. Methods for treating viral conditions
BR112012031464A2 (pt) 2010-06-10 2020-08-04 Aragon Pharmaceuticals, Inc. moduladores do receptor de estrogênio e os seus usos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
CA2820078C (en) 2010-12-16 2019-02-12 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
AU2011347718B2 (en) 2010-12-24 2016-06-23 Msd Oss B.V. N-substituted azetidine derivatives
SG11201403002RA (en) * 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
DK2828385T3 (en) 2012-03-23 2018-03-12 Codexis Inc BIOCATALIZATORS AND METHODS FOR SYNTHETIZING DERIVATIVES AND TRYPTAMIN AND TRYPTAMINE ANALOGS
CA2866222C (en) 2012-03-23 2022-01-11 Novartis Ag Chemical process for preparing spiroindolones and intermediates thereof
DE102012209622A1 (de) 2012-06-08 2013-12-12 Robert Bosch Gmbh Zahnradmaschine mit hydrodynamisch und hydrostatisch gelagertem Lagerzapfen
EP2682119A1 (en) 2012-07-03 2014-01-08 Université Libre de Bruxelles Aromatic N-heterocycle derivatives for use as medicine
CN104583215B (zh) * 2012-08-30 2016-12-07 霍夫曼-拉罗奇有限公司 二噁烯并-和噁嗪-[2,3-d]嘧啶pi3k抑制剂化合物及使用方法
EP2738173A1 (en) 2012-11-28 2014-06-04 Commissariat A L'energie Atomique Et Aux Energies Alternatives Heterocyclic compounds as inhibitors of the sodium iodide symporter
DK3004090T3 (en) 2013-05-28 2018-01-08 Astrazeneca Ab CHEMICAL COMPOUNDS
BR112015031903A8 (pt) 2013-06-19 2019-12-31 Seragon Pharmaceuticals Inc composto, sal farmaceuticamente aceitável, composição farmacêutica e uso de um composto
WO2014205136A1 (en) 2013-06-19 2014-12-24 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
AU2014342520B2 (en) 2013-10-28 2019-08-08 Drexel University Novel treatments for attention and cognitive disorders, and for dementia associated with a neurodegenerative disorder
EP3089747A1 (en) 2013-12-06 2016-11-09 F. Hoffmann-La Roche AG Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
AU2015228860A1 (en) 2014-03-13 2016-09-08 F. Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
JP2017507964A (ja) 2014-03-13 2017-03-23 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト エストロゲン受容体モジュレーターを用いた治療的組合せ
CN111978319B (zh) 2014-06-27 2023-08-11 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
US9845291B2 (en) 2014-12-18 2017-12-19 Genentech, Inc. Estrogen receptor modulators and uses thereof
CN112375078B (zh) 2014-12-18 2023-12-19 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
WO2016097073A1 (en) 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Derivatives of 2,3-diphenylchromene useful for the treatment of cancer
KR102710603B1 (ko) 2015-10-01 2024-09-27 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
WO2017136688A1 (en) 2016-02-05 2017-08-10 Inventisbio Inc. Selective estrogen receptor degraders and uses thereof

Also Published As

Publication number Publication date
KR102559719B1 (ko) 2023-07-26
JP7128169B2 (ja) 2022-08-30
UA122868C2 (uk) 2021-01-13
HUE050466T2 (hu) 2020-12-28
AU2015367509B2 (en) 2020-01-02
IL251370B (en) 2020-02-27
IL251370A0 (en) 2017-05-29
CL2017000814A1 (es) 2017-12-29
IL287326B2 (en) 2023-09-01
MX2017007489A (es) 2017-10-18
CR20170250A (es) 2017-07-19
HK1243074A1 (zh) 2018-07-06
CN107108611B (zh) 2020-09-25
TWI699363B (zh) 2020-07-21
US20210236473A1 (en) 2021-08-05
US20160175289A1 (en) 2016-06-23
EP3233852A1 (en) 2017-10-25
SG10202100799PA (en) 2021-03-30
KR102785474B1 (ko) 2025-03-26
AU2020200407B2 (en) 2021-04-08
TW202323253A (zh) 2023-06-16
NZ730448A (en) 2021-02-26
US9980947B2 (en) 2018-05-29
SG10201913913VA (en) 2020-03-30
RS60824B1 (sr) 2020-10-30
JP7792942B2 (ja) 2025-12-26
MA53837A (fr) 2021-11-10
WO2016097072A1 (en) 2016-06-23
EP3233852B1 (en) 2020-07-15
JP7446348B2 (ja) 2024-03-08
AU2021200352B2 (en) 2022-12-15
PH12017501140A1 (en) 2018-03-05
EP3760623B1 (en) 2026-03-18
BR112017007662A2 (pt) 2017-12-19
IL311006A (en) 2024-04-01
KR20250044940A (ko) 2025-04-01
TW201636348A (zh) 2016-10-16
TW202506643A (zh) 2025-02-16
KR20230113416A (ko) 2023-07-28
CN112375078B (zh) 2023-12-19
TWI874834B (zh) 2025-03-01
SI3233852T1 (sl) 2020-10-30
ZA202108745B (en) 2024-10-30
PT3233852T (pt) 2020-09-10
TW202028204A (zh) 2020-08-01
JP2022088416A (ja) 2022-06-14
NZ769496A (en) 2023-09-29
EP3760623A1 (en) 2021-01-06
US20250114338A1 (en) 2025-04-10
JP2020073493A (ja) 2020-05-14
KR20250044939A (ko) 2025-04-01
CA2963736A1 (en) 2016-06-23
MX2020003532A (es) 2020-07-29
PE20171330A1 (es) 2017-09-13
AU2021200352A1 (en) 2021-03-18
IL301960B2 (en) 2024-08-01
IL270653B (en) 2021-12-01
AU2020200407A1 (en) 2020-02-13
MY198354A (en) 2023-08-28
US10966963B2 (en) 2021-04-06
LT3233852T (lt) 2020-10-12
AU2015367509A1 (en) 2017-04-13
US20230045776A9 (en) 2023-02-09
SG11201704401TA (en) 2017-07-28
HRP20201396T1 (hr) 2020-11-27
JP2017538725A (ja) 2017-12-28
MX376763B (es) 2025-03-07
EA201791239A8 (ru) 2019-01-31
CN118005631A (zh) 2024-05-10
CN112457310A (zh) 2021-03-09
IL287326A (en) 2021-12-01
TW202534076A (zh) 2025-09-01
EA032311B1 (ru) 2019-05-31
JP6679147B2 (ja) 2020-04-15
MX2022007975A (es) 2022-07-05
BR112017007662A8 (pt) 2021-10-05
IL287326B1 (en) 2023-05-01
TWI784255B (zh) 2022-11-21
CN112375078A (zh) 2021-02-19
EA201791239A1 (ru) 2017-10-31
CN117865872A (zh) 2024-04-12
US12233052B2 (en) 2025-02-25
IL301960B1 (en) 2024-04-01
JP2024028785A (ja) 2024-03-05
CN112375077A (zh) 2021-02-19
CO2017003070A2 (es) 2017-07-11
US20180235945A1 (en) 2018-08-23
KR20170097651A (ko) 2017-08-28
ES2819448T3 (es) 2021-04-16
IL301960A (en) 2023-06-01
CN107108611A (zh) 2017-08-29
MX395013B (es) 2025-03-24
TWI875674B (zh) 2025-03-01
BR112017007662B1 (pt) 2021-11-03
DK3233852T3 (da) 2020-09-14
CL2019000431A1 (es) 2019-07-12

Similar Documents

Publication Publication Date Title
IL287326B1 (en) Tetrahydro-pyrido[3, 4-b]indole estrogen receptor modulators and their uses
IL258363B (en) Tetrahydro-h1-pyrido[4,3-b]indole anti-estrogenic drugs
EP3512842A4 (en) INDOLDER DERIVATIVES AS A DEGRADOR OF THE ESTROGEN RECEPTOR
PL3490565T3 (pl) Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
AU2015367620B2 (en) Unit, device and system for preparing beverage consumptions
IL247250A0 (en) Methods and compositions for modulating estrogen receptor mutants
ZA201605712B (en) Therapeutic combinations with estrogen receptor modulators
EP3169683A4 (en) Functionalised and substituted indoles as anti-cancer agents
HUE057451T2 (hu) 4-oxo-3,4-dihidro-1,2,3-benzotriazinok mint GPR139 modulátorai
EP3224261A4 (en) Opioid receptor modulators
EP3196609A4 (en) Dispersion and supply device and combination weighing device
IL249267A0 (en) Materials containing carbonitrile and their use for selective modulation of the androgen receptor
EP3237102A4 (en) Device for cavitational mixing
PT3157912T (pt) Composições parasiticidas compreendendo derivados de indole, seus métodos e suas utilizações
EP3149380A4 (en) Swivel device
IL252753A0 (en) History of indole and azaindole, their preparation and use
GB201515296D0 (en) Hydrogel compositions, methods for preparing the same and uses thereof
EP3224230A4 (en) Estrogen receptor modulators
WO2015196144A3 (en) Androgen receptor antagonists
HK1259498A1 (en) Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
AU2014900105A0 (en) Skirt Securing Device
HK1233666A1 (en) Fgf21 receptor agonists and uses thereof